JP2022538237A - B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 - Google Patents

B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 Download PDF

Info

Publication number
JP2022538237A
JP2022538237A JP2021576635A JP2021576635A JP2022538237A JP 2022538237 A JP2022538237 A JP 2022538237A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2022538237 A JP2022538237 A JP 2022538237A
Authority
JP
Japan
Prior art keywords
dose
subject
therapeutic
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021576635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538237A5 (cg-RX-API-DMAC7.html
Inventor
アーデレン,キンバリー
アブジョウブ,エイダ
ブランケンシップ,ジョン
コナー,アヌラダ
ドスタレク,ミレク
フレミング,トニー
ホームバーグ,ブライアン
ホン,コニー
ファン,ルー
ルー,ハイフイ
ジェイ. バナッセ,ケー.ゲイリー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022538237A publication Critical patent/JP2022538237A/ja
Publication of JP2022538237A5 publication Critical patent/JP2022538237A5/ja
Priority to JP2025087586A priority Critical patent/JP2025138634A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021576635A 2019-06-24 2020-06-22 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 Withdrawn JP2022538237A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025087586A JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962865381P 2019-06-24 2019-06-24
US62/865,381 2019-06-24
US201962940589P 2019-11-26 2019-11-26
US62/940,589 2019-11-26
US202062967401P 2020-01-29 2020-01-29
US62/967,401 2020-01-29
US202063034106P 2020-06-03 2020-06-03
US63/034,106 2020-06-03
PCT/IB2020/055872 WO2020261093A1 (en) 2019-06-24 2020-06-22 Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025087586A Division JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Publications (2)

Publication Number Publication Date
JP2022538237A true JP2022538237A (ja) 2022-09-01
JP2022538237A5 JP2022538237A5 (cg-RX-API-DMAC7.html) 2023-06-27

Family

ID=71738213

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576635A Withdrawn JP2022538237A (ja) 2019-06-24 2020-06-22 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2025087586A Pending JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025087586A Pending JP2025138634A (ja) 2019-06-24 2025-05-27 B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療

Country Status (10)

Country Link
US (1) US20220332821A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986569A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022538237A (cg-RX-API-DMAC7.html)
KR (1) KR20220024729A (cg-RX-API-DMAC7.html)
CN (2) CN114286828A (cg-RX-API-DMAC7.html)
AU (1) AU2020307471A1 (cg-RX-API-DMAC7.html)
CA (1) CA3144324A1 (cg-RX-API-DMAC7.html)
IL (1) IL289187A (cg-RX-API-DMAC7.html)
TW (1) TW202115114A (cg-RX-API-DMAC7.html)
WO (1) WO2020261093A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524854A (ja) * 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
KR20230069181A (ko) * 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
JP2024504454A (ja) * 2021-01-29 2024-01-31 上▲海▼翰森生物医▲薬▼科技有限公司 抗体-薬物コンジュゲート及びその医学的使用
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
TW202325743A (zh) * 2021-07-14 2023-07-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合cd38、bcma和cd3的抗原結合分子及其醫藥用途
CN113908395B (zh) * 2021-10-13 2024-05-17 科悦医疗(苏州)有限公司 一种促醒仪
EP4426437A4 (en) * 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
KR20260057078A (ko) * 2023-08-18 2026-04-27 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
BRPI0413533A (pt) 2003-09-09 2006-10-10 Hoffmann La Roche derivados de malonamida que bloqueiam a atividade de gama-secretase
EP1680406A1 (en) 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
EP1702626B1 (en) 2003-12-30 2011-11-30 Kowa Company, Ltd. Screening method for gamma-secretase inhibitors
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA2641013A1 (en) 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
US20110257163A1 (en) 2007-08-07 2011-10-20 Schering Corporation Gamma secretase modulators
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
US9096582B2 (en) 2011-10-31 2015-08-04 Merck Sharp & Dohme Corp Gamma secretase modulators
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
EP2925313A4 (en) 2012-11-29 2016-05-11 Merck Sharp & Dohme SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS
UY36401A (es) * 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
JP6696982B2 (ja) * 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3および腫瘍抗原に結合するヘテロ二量体抗体
HK1245171A1 (zh) * 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
EP3324965A4 (en) 2015-07-24 2019-07-03 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
CN109310755A (zh) * 2016-02-02 2019-02-05 卡德门企业有限公司 Pd-l1和kdr的双特异性结合蛋白
US11124577B2 (en) * 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524854A (ja) * 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用

Also Published As

Publication number Publication date
KR20220024729A (ko) 2022-03-03
CN119679936A (zh) 2025-03-25
CN114286828A (zh) 2022-04-05
US20220332821A1 (en) 2022-10-20
IL289187A (en) 2022-02-01
JP2025138634A (ja) 2025-09-25
WO2020261093A1 (en) 2020-12-30
AU2020307471A1 (en) 2022-01-27
TW202115114A (zh) 2021-04-16
EP3986569A1 (en) 2022-04-27
CA3144324A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP2025138634A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
US12024570B2 (en) Anti-CTLA-4 antibodies and uses thereof
CN114929343B (zh) 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
US20240117054A1 (en) Proteins binding nkg2d, cd16 and flt3
JP7274426B2 (ja) 抗gitrアゴニスト抗体での癌の処置
CN113004391A (zh) 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
CN106068275A (zh) 抗pd‑1的人抗体
TW201726730A (zh) 抗lag3抗體及其用途
TW202340247A (zh) 結合nkg2d、cd16、及5t4之蛋白質
TW201124534A (en) Dual variable domain immunoglobulins and uses thereof
JP2021503911A (ja) 抗ox40抗体及びその用途
US20240124607A1 (en) Proteins binding nkg2d, cd16, and ceacam5
JP2024097985A (ja) 抗gitr抗体およびその使用
US20240270849A1 (en) Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodies
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250822